Navigation Links
New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications
Date:11/17/2009

LEIDEN, The Netherlands, November 17 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke. Based on novel action mechanisms, new drugs may be discovered with the potential to prevent vascular complications in patients with hypertension: an opportunity to improve the quality of life for over a billion people worldwide. This collaboration, involving 3.4 million euros, 9 new research positions, unique materials and exchange of know-how, is scheduled to last 3 years.

Jan Danser, Professor of Pharmacology at Erasmus MC says: "Ideally, new antihypertensive drugs not only lower blood pressure, but also offer organ protection. Our project studies the consequences of blocking the biological pathways in cells and organs that lead to hypertension. As such, the project will pave the way towards finding new ways to better treat hypertension and its associated vascular complications." Additionally, the project will focus on finding new modalities for the treatment of fibrosis and pulmonary hypertension, especially in children.

Hypertension, or high blood pressure, is a leading risk factor for coronary heart disease, renal insufficiency, pulmonary fibrosis and stroke. Hypertension often results in vascular complications and end-organ damage: major organs like the heart, kidneys, lung, brain and eyes, which are fed by the circulatory system, are affected by fluctuations in blood pressure. The number of people suffering from high blood pressure worldwide is increasing: 1 billion people are currently affected, but estimates predict that in 2025 the number will exceed 1.5 billion. Despite the high occurrence and sometimes great burden of the disease, available treatments are far from being sufficient. For children suffering from hypertension, an adequate treatment does not even exist.

The Netherlands Heart Foundation also supports this research. Hans Stam, director of the Netherlands Heart Foundation says: "Hypertension is a major risk factor for cardiovascular diseases such as myocardial infarction, heart failure and stroke. Unfortunately, antihypertensive medication fails to lower blood pressure sufficiently in numerous cases. For instance, research funded by the Netherlands Heart Foundation showed that 25% of the patients did not benefit from treatment with ACE inhibitors. An effective treatment of hypertension is of the utmost importance in our battle against cardiovascular diseases. The Netherlands Heart Foundation welcomes this new consortium and its efforts to explore new and more effective hypertension therapies."

SOURCE Top Institute Pharma (TI Pharma)


'/>"/>
SOURCE Top Institute Pharma (TI Pharma)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. TargetEx Leads the European Cancer Research Consortium
2. Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies
3. International science consortium publishes analysis of domestic cattle genome sequence
4. PCI Biotech-led Consortium Awarded EUR1.1 m Eurostars Grant for siRNA
5. NewCardio Joins the Cardiac Safety Research Consortium
6. Genstruct Added to The Biomarker Consortiums Rapidly Growing Roster of Industry Experts
7. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
8. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
9. Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
10. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
11. Advanced Energy Consortium will develop micro and nanosensors to boost energy production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):